Andrew Kuykendall, MD
Internal Medicine · Tampa, FLNPI 1154697738
Payments from drug & device makers
Across 612 payments — averaging $4885.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$916K
- Janssen Research & Development, LLC$655K
- Incyte Corporation$427K
- Blueprint Medicines Corporation$374K
- GSK$266K
- Geron Corporation$180K
- plus $172K from 18 others
Across 1 payment — averaging $142.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$143
What the payments were for
- Consulting fees$201,79863%
- Speaking & faculty fees$96,60530%
- Travel & lodging$18,6076%
- Food & beverage$4,8111%
- Education$910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 13 | $916,138 |
| Janssen Research & Development, LLC | 61 | $655,447 |
| Incyte Corporation | 182 | $426,860 |
| Blueprint Medicines Corporation | 78 | $374,132 |
| GSK | 33 | $266,268 |
| Geron Corporation | 109 | $179,689 |
| Bristol Myers Squibb | 17 | $36,449 |
| AbbVie | 42 | $29,879 |
| Merck | 13 | $18,788 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $18,147 |
| E.r. Squibb & Sons, L.L.C. | 7 | $14,034 |
| Morphosys, US Inc. | 9 | $13,531 |
| Sanofi US Services Inc. | 7 | $10,662 |
| Karyopharm Therapeutics Inc. | 11 | $8,590 |
| Pharmaessentia USA Corporation | 5 | $8,162 |
| Novartis Pharma AG | 1 | $4,725 |
| Agios Pharmaceuticals, Inc. | 1 | $4,075 |
| CTI Biopharma Corp. | 3 | $2,876 |
| Jubilant Therapeutics Inc | 1 | $1,000 |
| Sobi, Inc | 1 | $196 |
| TELA Bio, Inc. | 1 | $168 |
| AstraZeneca | 1 | $137 |
| Boston Scientific | 1 | $88 |
| Taiho Oncology, Inc. | 1 | $55 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,990,097 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 381 | $6,904,743 |
| OjjaaraMomelotinib Dihydrochloride | 75 | $2,084,358 |
| AyvakitAvapritinib | 51 | $1,968,263 |
| BesremiRopeginterferon Alfa-2b-Njft | 54 | $872,280 |
| VonjoPacritinib Citrate | 21 | $548,892 |
| PegasysPeginterferon Alfa-2a | 42 | $170,794 |
| VenclextaVenetoclax | 18 | $58,760 |
| EliquisApixaban | 36 | $24,688 |
| Hydroxyurea | 102 | $2,424 |
| Allopurinol | 30 | $95 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $426,860 | $6,904,743381 claims |
| GSKOjjaara | $266,268 | $2,084,35875 claims |
| Blueprint Medicines CorporationAyvakit | $374,132 | $1,968,26351 claims |
| Pharmaessentia USA CorporationBesremi | $8,162 | $872,28054 claims |
| AbbVieVenclexta | $29,879 | $58,76018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Tampa
- Jhanelle GrayTampa$20.8M
- Sady AlpizarTampa$13.5M
- Karon LociceroTampa$6.6M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.